Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy

Publisher： Karger

E-ISSN： 1423-0232|59|4|296-301

ISSN： 0030-2414

Source： Oncology, Vol.59, Iss.4, 2000-11, pp. : 296-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 301-306

Karger

Access to resources Recommend Favorite

Use of Hematopoietic Growth Factors in Elderly Patients Receiving Cytotoxic Chemotherapy

By  

Oncology Research and Treatment, Vol. 25, Iss. 1, 2002-03 ,pp. : 32-39

Karger

Access to resources Recommend Favorite

Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 888-897

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 10, 2015-10 ,pp. : 888-897

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sustained Partial Remission of Metastatic Pancreatic Cancer Following Systemic Chemotherapy with Gemcitabine and Oxaliplatin plus Adjunctive Treatment with Mistletoe Extract

By  

Oncology Research and Treatment, Vol. 33, Iss. 11, 2010-10 ,pp. : 617-619

Karger

Access to resources Recommend Favorite